# Citi

Type: Company (C)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/citi
Canonical HTML page: https://getbiobrief.com/entity/citi

## Recent coverage (1 stories)

### Hims & Hers Surges 41% on Landmark GLP-1 Supply Deal with Novo Nordisk
2026-03-10 00:20:37 · Sentiment: Positive · Impact: 7/10 · Sources: 3

Hims & Hers Health shares skyrocketed 41% following a strategic agreement with Novo Nordisk to distribute branded GLP-1 medications, including Ozempic, directly through its telehealth platform. The deal effectively ends a high-stakes patent dispute and transitions the company away from controversial compounded formulations toward FDA-approved branded therapies.
Full story: https://getbiobrief.com/story/hims-hers-novo-nordisk-glp1-partnership

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.